Colorectal Cancer Drugs Market: By Therapy (Adjuvant Chemotherapy, Palliative Chemotherapy, Immuno Therapy, Neo Adjuvant Chemotherapy), By Drug Type (Capecitabine, Irinotecan, Fluorouracil, Trifluridine/tipiracil, Oxaliplatin, Others), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies) and Geography  

Purchase Option

$ 4400
$ 6600
$ 8900

Colorectal Cancer Drugs Market size was valued at 15.5 billion in 2023 and is expected to reach 23.0 billion by 2030, at a significant CAGR of 8.5% from 2024-2030. Colorectal cancer is also known as bowel cancer. It refers to the abnormal growth of the cells in colon and rectum due to cancer. Colorectal cancer starts either in the colon and rectum. Cancer starts as a polyp in the inner wall of the colon or rectum. These polyps can be benign or malignant. Some of the risk factors that can cause colorectal cancer are lifestyle changes, old age, genetic disorders, family history, and inflammatory bowel disease. Some of the symptoms of colorectal cancer are blood in stool, decrease in appetite, constipation, weight loss, nausea, bloating, and pelvic pain. Colorectal cancer is the third most common cancer in the world. Huge government initiatives taken by the nations are booming up the growth of the colorectal cancer drugs treatment market globally. Biologics such as Zaltrap (Ziv-Aflibercept), Erbitux (Cetuximab), Avastin (Bevacizumab) are using rapidly for the treatment for colorectal cancer that are used as a targeted therapy and they acts only on the malignant cells. Market players in the market forming strategic alliances and partnerships to increase their market share.

Global Colorectal Cancer Drugs Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

8.5%

Largest Market

Asia-Pacific

Fastest Growing Market

North-America
Colorectal Cancer Drugs Market Dynamics

Global colorectal cancer market is driven by some of the major factors such as increasing prevalence of colorectal cancer, technological advancements in the cancer therapy, aging population, and raise in consumer awareness about colorectal cancers. However, high costs of screening tests and drugs, lack of knowledge are some of the restraints that are hampering the growth of the global market.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Global Colorectal Cancer Drugs Market Segmentation

By Therapy
  • Adjuvant Chemotherapy
  • Palliative Chemotherapy
  • Immuno Therapy
  • Neo Adjuvant Chemotherapy
By Drug Type
  • Capecitabine
  • Irinotecan
  • Fluorouracil
  • Trifluridine/tipiracil
  • Oxaliplatin
  • Others
By Distribution Channel
  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
By Geography
  • Latin America
  • North America
  • Asia Pacific
  • Europe
  • Middle East and Africa

Frequently Asked Questions

The Colorectal cancer drugs market size was valued at USD 15.5 billion in 2023

The key segments covered in the colorectal cancer drugs market are technology, components, application, and end-users.

The Colorectal cancer drugs market key players are Amgen Inc. (U.S), Bristol-Myers Squibb Company (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Bayer AG (Germany), Merck & Co., Inc. (U.S.), Sanofi (France)

1. Executive Summary
2. Global Colorectal Cancer Drugs Market Introduction 
2.1.Global Colorectal Cancer Drugs Market  - Taxonomy
2.2.Global Colorectal Cancer Drugs Market  - Definitions
2.2.1.Therapy
2.2.2.Drug Type
2.2.3.Distribution Channel
2.2.4.Region
3. Global Colorectal Cancer Drugs Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4. Global Colorectal Cancer Drugs Market Analysis, 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Colorectal Cancer Drugs Market  By Therapy, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. Adjuvant Chemotherapy
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Palliative Chemotherapy
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Immuno Therapy
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Neo Adjuvant Chemotherapy
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
6.Global Colorectal Cancer Drugs Market  By Drug Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. Capecitabine
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Irinotecan
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Fluorouracil
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Trifluridine/tipiracil
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
6.5. Oxaliplatin
6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.5.3. Market Opportunity Analysis 
6.6. Others
6.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.6.3. Market Opportunity Analysis 
7. Global Colorectal Cancer Drugs Market  By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. Retail Pharmacies
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Hospital Pharmacies
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Online Pharmacies
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
8. Global Colorectal Cancer Drugs Market  By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9. North America Colorectal Cancer Drugs Market, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
9.1. Therapy Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Adjuvant Chemotherapy
9.1.2.Palliative Chemotherapy
9.1.3.Immuno Therapy
9.1.4.Neo Adjuvant Chemotherapy
9.2.  Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Capecitabine
9.2.2.Irinotecan
9.2.3.Fluorouracil
9.2.4.Trifluridine/tipiracil
9.2.5.Oxaliplatin
9.2.6.Others
9.3.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Retail Pharmacies
9.3.2.Hospital Pharmacies
9.3.3.Online Pharmacies
9.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10. Europe Colorectal Cancer Drugs Market, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
10.1. Therapy Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Adjuvant Chemotherapy
10.1.2.Palliative Chemotherapy
10.1.3.Immuno Therapy
10.1.4.Neo Adjuvant Chemotherapy
10.2.  Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Capecitabine
10.2.2.Irinotecan
10.2.3.Fluorouracil
10.2.4.Trifluridine/tipiracil
10.2.5.Oxaliplatin
10.2.6.Others
10.3.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Retail Pharmacies
10.3.2.Hospital Pharmacies
10.3.3.Online Pharmacies
10.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
10.4.6.Rest of EU
11. Asia Pacific (APAC) Colorectal Cancer Drugs Market, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
11.1. Therapy Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Adjuvant Chemotherapy
11.1.2.Palliative Chemotherapy
11.1.3.Immuno Therapy
11.1.4.Neo Adjuvant Chemotherapy
11.2.  Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Capecitabine
11.2.2.Irinotecan
11.2.3.Fluorouracil
11.2.4.Trifluridine/tipiracil
11.2.5.Oxaliplatin
11.2.6.Others
11.3.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Retail Pharmacies
11.3.2.Hospital Pharmacies
11.3.3.Online Pharmacies
11.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12.Middle East and Africa (MEA) Colorectal Cancer Drugs Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
12.1. Therapy Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Adjuvant Chemotherapy
12.1.2.Palliative Chemotherapy
12.1.3.Immuno Therapy
12.1.4.Neo Adjuvant Chemotherapy
12.2.  Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Capecitabine
12.2.2.Irinotecan
12.2.3.Fluorouracil
12.2.4.Trifluridine/tipiracil
12.2.5.Oxaliplatin
12.2.6.Others
12.3.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Retail Pharmacies
12.3.2.Hospital Pharmacies
12.3.3.Online Pharmacies
12.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13. Latin America Colorectal Cancer Drugs Market,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
13.1. Therapy Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Adjuvant Chemotherapy
13.1.2.Palliative Chemotherapy
13.1.3.Immuno Therapy
13.1.4.Neo Adjuvant Chemotherapy
13.2.  Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Capecitabine
13.2.2.Irinotecan
13.2.3.Fluorouracil
13.2.4.Trifluridine/tipiracil
13.2.5.Oxaliplatin
13.2.6.Others
13.3.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Retail Pharmacies
13.3.2.Hospital Pharmacies
13.3.3.Online Pharmacies
13.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.Amgen Inc. (U.S)
14.2.2.Bristol-Myers Squibb Company (U.S)
14.2.3.F. Hoffmann-La Roche Ltd. (Switzerland)
14.2.4.Bayer AG (Germany)
14.2.5.Merck & Co., Inc. (U.S)
14.2.6.Sanofi (France)
15. Research Methodology 
16. Appendix and Abbreviations 
  • Amgen Inc. (U.S)
  • Bristol-Myers Squibb Company (U.S)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Bayer AG (Germany)
  • Merck & Co., Inc. (U.S)
  • Sanofi (France)

Adjacent Markets